COVID-19: Combined use of Avegan and Fusan, clinical research: University of Tokyo research team started
Tokyo University:
On May 8, it was announced that it will start clinical trials to co-administer the influenza drug Avigan and the pancreatitis drug Fusan to patients with novel coronavirus infections.
Avigan: It has the effect of suppressing viral growth in cells. ,
Fusan: It has the effect of preventing viruses from entering cells.
Studies on administration alone are progressing, but studies on combination are the first trials in Japan.
The research team says, “By using drugs with different functions, synergistic effects can be expected.”
Trial method:
Conducted at the University of Tokyo Hospital and Keio University Hospital.
Targeting patients aged 20 to 74 with pulmonary inflammation,
When only Avigan is administered
Both when administered
Compare the therapeutic effects.
Confirm safety such as side effects.
Kyodo communication